Active, not recruitingPhase 3NCT06706622
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
Studying Multiple system atrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- H. Lundbeck A/S
- Principal Investigator
- Email contact via H. Lundbeck A/SH. Lundbeck A/S
- Intervention
- Amlenetug(drug)
- Enrollment
- 357 target
- Eligibility
- 40-75 years · All sexes
- Timeline
- 2024 – 2029
Study locations (30)
- Mayo Clinic, Scottsdale, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- University of California, San Francisco Neurosciences Clinical Research Unit, San Francisco, California, United States
- CenExel Rocky Mountain Clinical Research, LLC, Englewood, Colorado, United States
- Yale New Haven Health, North Haven, Connecticut, United States
- Parkinson's Disease And Movement Disorder Center Of Boca Raton, Boca Raton, Florida, United States
- University of Florida Norman Fixel Institute for Neurological Diseases, Gainesville, Florida, United States
- Indiana Health University, Indianapolis, Indiana, United States
- Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- QUEST Research Institute, Farmington Hills, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- University Nebraska Medical Center, Omaha, Nebraska, United States
- NYU Medical Center - Dysautonomia center, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06706622 on ClinicalTrials.govOther trials for Multiple system atrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07446894MSA-01 in Multiple System AtrophyTokyo University
- RECRUITINGPHASE2NCT07197866An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System AtrophyTeva Branded Pharmaceutical Products R&D LLC
- ENROLLING BY INVITATIONNCT07081841AB-1005 Long-Term Follow-up StudyAskBio Inc
- RECRUITINGPHASE1, PHASE2NCT06831500Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.Julien Bally
- RECRUITINGEARLY PHASE1NCT06765733The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System AtrophyBeijing Tiantan Hospital
- RECRUITINGPHASE2NCT06868628A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)Tiziana Life Sciences LTD
- RECRUITINGNCT07353463Shanghai Clinical Cohort - Parkinson's Disease (Reserve)Ruijin Hospital
- RECRUITINGEARLY PHASE1NCT06891703[18F]ACI-15916 PET in α-synucleinopathiesAC Immune SA